Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 2:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 3,408 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Inflammatory Clear all
Recruiting Not applicable Interventional

Remote Physical Activity Programming to Improve Outcomes in Cancer Survivors With and Without Type 2 Diabetes

NCT06725953
View directory record Official record
Conditions
Cancer Survivorship, Chemotherapy Side Effects
Interventions
Social Cognitive Theory-based, Technology-delivered Physical Activity Program
Behavioral
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 26, 2026, 2:12 AM EDT
Terminated Not applicable Interventional

Peri-Atrial Inflammatory Fat and Atrial Fibrillation

NCT04186169
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Catheter ablation
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 26, 2026, 2:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of a Dietary Supplement on Lipoprotein Lipids and Inflammatory Markers

NCT03118583
View directory record Official record
Conditions
Healthy Volunteers
Interventions
300 mg/day of dietary supplement containing carrageenan
Dietary Supplement
Lead sponsor
Midwest Center for Metabolic and Cardiovascular Research
Other
Eligibility
25 Years to 69 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Oct 26, 2026, 2:12 AM EDT
Completed Phase 3 Interventional Results available

Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens

NCT02714595
View directory record Official record
Conditions
Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI), Hospital Acquired Pneumonia (HAP), Complicated Urinary Tract Infection (cUTI), Sepsis, Ventilator Associated Pneumonia (VAP)
Interventions
Cefiderocol, Best Available Therapy
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Hartford, Connecticut • Newark, Delaware • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Oct 26, 2026, 2:12 AM EDT
Completed Phase 2 Interventional Results available

ICON-2: FMT and Bezlotoxumab Compared to FMT and Placebo for Patients With IBD and CDI

NCT03829475
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Clostridium Difficile Infection
Interventions
Bezlotoxumab, Placebo, Fecal Microbiota Transplantation
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 26, 2026, 2:12 AM EDT
Completed Phase 2 Interventional Results available

Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis

NCT01393405
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Methotrexate
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
31
States / cities
Los Angeles, California • Denver, Colorado • Winter Park, Florida + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 26, 2026, 2:12 AM EDT
Completed Not applicable Interventional

Metal Ion Release From an FDA-Approved Metal-on-Metal Total Hip Replacement Implant

NCT00962351
View directory record Official record
Conditions
Non-inflammatory Degenerative Joint Disease
Interventions
Total Hip Replacement
Procedure
Lead sponsor
Anderson Orthopaedic Research Institute
Other
Eligibility
40 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
1
States / cities
Alexandria, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 17, 2015 · Synced Oct 26, 2026, 2:12 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Oral OKT3 for the Treatment of Active Ulcerative Colitis

NCT01287195
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Oral OKT3, Omeprazole
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Oct 26, 2026, 2:12 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Postpartum NSAIDS and Maternal Hypertension

NCT03824119
View directory record Official record
Conditions
Preeclampsia, Gestational Hypertension, Superimposed Preeclampsia, Chronic Hypertension in Obstetric Context
Interventions
Ibuprofen 600 mg, Standard Postpartum Care without NSAIDs
Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2020 · Synced Oct 26, 2026, 2:12 AM EDT
Completed Early Phase 1 Interventional

Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases

NCT02925351
View directory record Official record
Conditions
Autoimmune Disease, Crohn Disease, Inflammatory Disorder, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Takayasu Arteritis
Interventions
Computed Tomography, Fluorine F 18 Clofarabine, Positron Emission Tomography
Procedure · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2020 · Synced Oct 26, 2026, 2:12 AM EDT
Completed Not applicable Interventional

Effectiveness of Interleukin-2 (IL-2) Plus Anti-HIV Therapy in HIV-Positive Patients

NCT00001131
View directory record Official record
Conditions
HIV Infections
Interventions
Aldesleukin, HAART
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2015 · Synced Oct 26, 2026, 2:12 AM EDT
Not listed No phase listed Observational

Journey™ UNI Post Market Clinical Follow-Up

NCT03442231
View directory record Official record
Conditions
Non-inflammatory Degenerative Joint Disease
Interventions
Journey UNI Unicompartmental Knee System
Device
Lead sponsor
Smith & Nephew, Inc.
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
Scottsdale, Arizona • Park Ridge, Illinois • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 26, 2026, 2:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Blood-Stage Plasmodium Vivax Cell Bank

NCT05095272
View directory record Official record
Conditions
Malaria
Interventions
HMPBS02-Pv
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Oct 26, 2026, 2:12 AM EDT
Completed Not applicable Interventional

Effect of Whole Grain Diet on Insulin Sensitivity, Advanced Glycation End Products and Inflammatory Markers in Pre-diabetes

NCT01248286
View directory record Official record
Conditions
Diabetes, Prediabetes
Interventions
Whole grain rice, Refined grain rice
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2013 · Synced Oct 26, 2026, 2:12 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)

NCT06137183
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Vixarelimab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
15
States / cities
Camarillo, California • Los Angeles, California • Mission Hills, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 26, 2026, 2:12 AM EDT
Terminated Not applicable Interventional

Study of the Effect of Regional Nerve Blocks on Pain and Inflammation After Video Assisted Thorascopic Lung Surgery

NCT00639795
View directory record Official record
Conditions
Pain
Interventions
Thoracic Paravertebral Nerve Block
Procedure
Lead sponsor
Memorial Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Johnstown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 3, 2013 · Synced Oct 26, 2026, 2:12 AM EDT
Completed Not applicable Interventional

Using Biomarkers to Optimize Antibiotic Strategies in Sepsis

NCT02207114
View directory record Official record
Conditions
Sepsis
Interventions
Biomarker Algorithm Intervention
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 26, 2026, 2:12 AM EDT
Not listed Phase 3 Interventional

Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19

NCT04351152
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19) Pneumonia
Interventions
Lenzilumab, Standard of Care
Biological · Drug
Lead sponsor
Humanigen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
18
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 26, 2026, 2:12 AM EDT
Completed Phase 4 Interventional Results available

Minocycline to Treat Childhood Regressive Autism

NCT00409747
View directory record Official record
Conditions
Autism, Minocycline, Regressive Autism
Interventions
Minocycline
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
3 Years to 12 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2015 · Synced Oct 26, 2026, 2:12 AM EDT
Completed Phase 1 Interventional Results available

Metronidazole Pharmacokinetics (PK) in Premature Infants

NCT01222585
View directory record Official record
Conditions
Serious Systemic Infections, Necrotizing Enterocolitis
Interventions
Metronidazole
Drug
Lead sponsor
Michael Cohen-Wolkowiez
Other
Eligibility
Up to 90 Days
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
3
States / cities
Orange, California • Wichita, Kansas • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 26, 2026, 2:12 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Tolerability of BAF312 in Patients With Polymyositis

NCT01801917
View directory record Official record
Conditions
Polymyositis
Interventions
Placebo, BAF312
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 26, 2026, 2:12 AM EDT
Completed No phase listed Observational

Optimizing Clinical Use of Polymyxin B

NCT02682355
View directory record Official record
Conditions
Pneumonia, Blood Stream Infection, Urinary Tract Infections, Respiratory Tract Infection (Including Tracheobronchitis), Sepsis
Interventions
Not listed
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
3
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Oct 26, 2026, 2:12 AM EDT
Not yet recruiting No phase listed Observational

Guselkumab for Overlap Inflammatory Bowel Disease and Spondyloarthritis

NCT07602517
View directory record Official record
Conditions
Spondyloarthritis, Inflammatory Bowel Diseases
Interventions
Guselkumab
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 26, 2026, 2:12 AM EDT
Not listed Phase 4 Interventional

Optimizing Cimzia in Crohn's Patients

NCT01024647
View directory record Official record
Conditions
Crohn's Disease
Interventions
certolizumab pegol
Biological
Lead sponsor
Atlanta Gastroenterology Associates
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 5, 2012 · Synced Oct 26, 2026, 2:12 AM EDT